Evidence map›Paper›PMID 33768319›Full record

ArticleVirchows Archiv : an international journal of pathology2021

TERT promoter mutation in sebaceous neoplasms.

María-Teresa Muñoz-Jiménez, Leyla Blanco, Yolanda Ruano, Rosario Carrillo, Ángel Santos-Briz, Erika Riveiro-Falkenbach, Luis Requena, Heinz Kutzner, María Concepción Garrido, José-Luis Rodríguez-Peralto

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

María-Teresa Muñoz-JiménezDepartment of Pathology, Medical School, Universidad Complutense, Instituto i+12, Hospital Universitario 12 de Octubre, CIBERONC, Madrid, Spain.ORCID https://orcid.org/0000-0002-7860-0685
Leyla BlancoDepartment of Pathology, Medical School, Universidad Complutense, Instituto i+12, Hospital Universitario 12 de Octubre, CIBERONC, Madrid, Spain.
Yolanda RuanoDepartment of Pathology, Medical School, Universidad Complutense, Instituto i+12, Hospital Universitario 12 de Octubre, CIBERONC, Madrid, Spain.ORCID https://orcid.org/0000-0001-6116-9369
Rosario CarrilloDepartment of Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain.ORCID https://orcid.org/0000-0001-8723-6494
Ángel Santos-BrizDepartment of Pathology, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.ORCID https://orcid.org/0000-0002-4711-5142
Erika Riveiro-FalkenbachDepartment of Pathology, Medical School, Universidad Complutense, Instituto i+12, Hospital Universitario 12 de Octubre, CIBERONC, Madrid, Spain.ORCID https://orcid.org/0000-0002-0420-6781
Luis RequenaDepartment of Dermatology, Fundación Jiménez Díaz, Madrid, Spain.ORCID https://orcid.org/0000-0002-1045-4810
Heinz KutznerDermatopathology Department, Dermatopathologie Friedrichshafen, Friedrichshafen, Germany.ORCID https://orcid.org/0000-0001-6248-3050
María Concepción GarridoDepartment of Pathology, Medical School, Universidad Complutense, Instituto i+12, Hospital Universitario 12 de Octubre, CIBERONC, Madrid, Spain.ORCID https://orcid.org/0000-0002-5400-0693
José-Luis Rodríguez-PeraltoDepartment of Pathology, Medical School, Universidad Complutense, Instituto i+12, Hospital Universitario 12 de Octubre, CIBERONC, Madrid, Spain. jrperalto@salud.madrid.org.
Hospital Universitario 12 De Octubre · ESComplejo Hospitalario de Salamanca · ESDermatopathologie Friedrichshafen · DEHospital Universitario Fundación Jiménez Díaz · ESHospital Universitario Ramón y Cajal · ESResearch Institute Hospital 12 de Octubre · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TERT promoter (TERTp) mutations widely occur in multiple human neoplasms, and they have been related to different clinicopathological features. To date, this mutation has not been identified in sebaceous tumors. Here, we analyzed TERTp mutations in 91 sebaceous neoplasms (17 adenomas, 45 sebaceomas, and 29 carcinomas). We detected mutations in 26.7% (8 of 29) of sebaceous carcinomas by pyrosequencing and Sanger sequencing. No mutation was detected in adenomas or sebaceomas. The difference was significant between sebaceoma and carcinoma. The most frequent TERTp mutations were C228T and C250T in 37.5% (3 of 8) of mutated cases each one. The mutation was not associated with poor clinical evolution. Using NGS, 20 of 29 (68.5%) sebaceous carcinomas harbored mutations in 8 of the 30 genes analyzed (TP53, TERTp, EGFR, ATRX, PDGFRA, CDKN2A, PTEN, and ACVR1). With immunohistochemistry, only 1 of 8 (12.5%) TERTp-mutated carcinomas lacked mismatch repair (MMR) protein expression compared to 6 of 21 (31.6%) of non-mutated ones. Sebaceous carcinomas with MMR protein expression had significantly higher frequency of total mutations and TP53 and TERTp mutations than MMR protein-deficient carcinomas. In conclusion, TERTp mutation has been detected in sebaceous carcinomas, and its presence could be useful to differentiate sebaceous carcinoma from sebaceoma, a difficult histopathological challenge.

Indexed as

MutationPromoter Regions, GeneticAdenomaAgedAged, 80 and overBiomarkers, TumorCarcinomaDNA Mismatch RepairDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryMaleMiddle AgedBiomarkers, TumorTelomeraseTERT protein, humanTP53 protein, humanTumor Suppressor Protein p53Mismatch repair proteinsSebaceous neoplasmsSequencingTERT promoter mutation

Identifiers

PMID33768319
OpenAlexW3136294918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.